KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy

被引：0
|
作者：
Cunha Pereira, T. [1 ]
Salgueiro, F. [1 ]
Monteiro, A. [1 ]
Felix Soares, R. [1 ]
Macedo, F. [1 ]
Jacinto, P. [1 ]
Paulo, J. [1 ]
Bonito, N. [1 ]
Marques, M. [1 ]
Ribeiro, J. [1 ]
Sousa, G. [1 ]
机构：
[1] Portuguese Oncol Inst Coimbra Francisco Gentil, Coimbra, Portugal
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.307
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-225
引用
收藏
页码：S163 / S164
页数：2
相关论文
共 50 条
  • [1] Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer
    Strickler, John H.
    Hurwitz, Herbert I.
    ONCOLOGIST, 2012, 17 (04): : 513 - 524
  • [2] KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer
    Ergun, Yakup
    Acikgoz, Yusuf
    Bal, Oznur
    Ucar, Gokhan
    Dirikoc, Merve
    Yildirim, Eda Caliskan
    Akdeniz, Nadiye
    Uncu, Dogan
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2019, 19 (12) : 1131 - 1140
  • [3] Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer
    Ito, Mamoru
    Kusaba, Hitoshi
    Mukaide, Satomi
    Kishimoto, Junji
    Shimokawa, Hozumi
    Tamura, Shingo
    Makiyama, Akitaka
    Hirano, Gen
    Oda, Hisanobu
    Shirakawa, Tsuyoshi
    Komoda, Masato
    Uchino, Keita
    Tanaka, Risa
    Mitsugi, Kenji
    Esaki, Taito
    Arita, Shuji
    Ariyama, Hiroshi
    Akashi, Koichi
    Baba, Eishi
    ANTI-CANCER DRUGS, 2017, 28 (10) : 1166 - 1173
  • [4] Evaluation of serum mid-infrared spectroscopy as new prognostic marker for bevacizumab-based chemotherapy in first-line treatment of metastatic colorectal cancer
    Chautard, R.
    Leger, J.
    Bouche, O.
    Borg, C.
    Douillard, J-Y.
    Manfredi, S.
    Terrebonne, E.
    Capitain, O.
    Spano, J-P.
    Caulet, M.
    Raoul, W.
    Gueguinou, M.
    Herault, O.
    Ferru, A.
    Pobel, C. J.
    Sire, O.
    Lecomte, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S571 - S571
  • [5] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [6] Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis
    Modest, Dominik Paul
    Reinacher-Schick, Anke
    Stintzing, Sebastian
    Giessen, Clemens
    Tannapfel, Andrea
    Laubender, Ruediger Paul
    Brodowicz, Thomas
    Knittelfelder, Regina
    Vrbanec, Damir
    Schmiegel, Wolff
    Heinemann, Volker
    Zielinski, Christoph C.
    ANTI-CANCER DRUGS, 2012, 23 (06) : 666 - 673
  • [7] Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer
    Guiu, Boris
    Petit, Jean Michel
    Bonnetain, Franck
    Ladoire, Sylvain
    Guiu, Severine
    Cercueil, Jean-Pierre
    Krause, Denis
    Hillon, Patrick
    Borg, Christophe
    Chauffert, Bruno
    Ghiringhelli, Francois
    GUT, 2010, 59 (03) : 341 - 347
  • [8] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [9] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [10] KRAS MUTATIONS AND OUTCOME IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE CHEMOTHERAPY WITH OR WITHOUT CETUXIMAB
    Tejpar, Sabine
    Bokemeyer, Carsten
    Celik, Ilhan
    Schlichting, Michael
    Heeger, Steffen
    Van Cutsem, Eric
    ANNALS OF ONCOLOGY, 2011, 22 : v16 - v17
12345